Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Dimetacrine


Most recent articles on Dimetacrine

Most cited articles on Dimetacrine

Review articles on Dimetacrine

Articles on Dimetacrine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Dimetacrine

Images of Dimetacrine

Photos of Dimetacrine

Podcasts & MP3s on Dimetacrine

Videos on Dimetacrine

Evidence Based Medicine

Cochrane Collaboration on Dimetacrine

Bandolier on Dimetacrine

TRIP on Dimetacrine

Clinical Trials

Ongoing Trials on Dimetacrine at Clinical Trials.gov

Trial results on Dimetacrine

Clinical Trials on Dimetacrine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dimetacrine

NICE Guidance on Dimetacrine


FDA on Dimetacrine

CDC on Dimetacrine


Books on Dimetacrine


Dimetacrine in the news

Be alerted to news on Dimetacrine

News trends on Dimetacrine


Blogs on Dimetacrine


Definitions of Dimetacrine

Patient Resources / Community

Patient resources on Dimetacrine

Discussion groups on Dimetacrine

Patient Handouts on Dimetacrine

Directions to Hospitals Treating Dimetacrine

Risk calculators and risk factors for Dimetacrine

Healthcare Provider Resources

Symptoms of Dimetacrine

Causes & Risk Factors for Dimetacrine

Diagnostic studies for Dimetacrine

Treatment of Dimetacrine

Continuing Medical Education (CME)

CME Programs on Dimetacrine


Dimetacrine en Espanol

Dimetacrine en Francais


Dimetacrine in the Marketplace

Patents on Dimetacrine

Experimental / Informatics

List of terms related to Dimetacrine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Dimetacrine (Istonil, Istonyl, Linostil, Miroistonil), also known as dimethacrine and acripramine, is a tricyclic antidepressant (TCA) used in Europe and formerly in Japan for the treatment of depression.[1][2][3][4][5] It has imipramine-like effects; though, in a double-blind clinical trial against imipramine, dimetacrine was found to have lower efficacy in comparison and produced more weight loss and abnormal liver tests.[6][7] Little is known about the pharmacology of dimetacrine, but it can be inferred that it acts in a similar manner to other TCAs. If this is indeed the case, dimetacrine may induce severe cardiac toxicity in overdose (a side effect unique to the tricyclic class of antidepressants).

See also


  1. Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
  2. Affective disorders: perspective on ... - Google Books.
  3. José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  4. Taen S, Pöldinger W (December 1966). "[Dimethacrine (istonil), an acridane derivative with the antidepressive action]". Schweizerische Medizinische Wochenschrift (in German). 96 (48): 1616–20. PMID 6008540.
  5. Meyer R (May 1968). "[Contribution to the clinical evaluation of the antidepressive effect of dimethacrine (Istonil)]". Praxis (in German). 57 (20): 721–3. PMID 5756370.
  6. Abuzzahab FS (November 1973). "A double-blind investigation of dimethacrine versus imipramine in hospitalized depressive states". International Journal of Clinical Pharmacology, Therapy and Toxicology. 8 (3): 244–53. PMID 4149236.
  7. Mutschler, Ernst; Derendorf, Hartmut (1995). Drug actions: basic principles and therapeutic aspects. Stuttgart, Germany: Medpharm Scientific Pub. ISBN 0-8493-7774-9. Retrieved January 30, 2013.